An Integrated Multiple-Analyte Pharmacokinetic Model to Characterize Trastuzumab Emtansine (T-DM1) Clearance Pathways and to Evaluate Reduced Pharmacokinetic Sampling in Patients with HER2-Positive Metastatic Breast Cancer
Lu D, Joshi A, Wang B, Olsen S, Yi JH, Krop IE, Burris HA, Girish S. An Integrated Multiple-Analyte Pharmacokinetic Model to Characterize Trastuzumab Emtansine (T-DM1) Clearance Pathways and to Evaluate Reduced Pharmacokinetic Sampling in Patients with HER2-Positive Metastatic Breast Cancer. Clinical Pharmacokinetics 2013, 52: 657-672. PMID: 23553425, DOI: 10.1007/s40262-013-0060-y.Peer-Reviewed Original ResearchConceptsMetastatic breast cancerIntegrated population pharmacokinetic modelTotal trastuzumabPopulation pharmacokinetic modelT-DM1Pharmacokinetic dataPharmacokinetic profileBreast cancerClearance pathwaysPharmacokinetic samplingPharmacokinetic modelHER2-positive metastatic breast cancerPositive metastatic breast cancerHuman epidermal growth factor receptor 2Epidermal growth factor receptor 2Cytotoxic agent DM1Growth factor receptor 2T-DM1 treatmentEnd of infusionFactor receptor 2Serum concentration dataMonoclonal antibody trastuzumabTrastuzumab pharmacokineticsFaster clearance rateTaxane chemotherapy